Table 3.
Correlations between clinicopathologic parameters and XPC Ala499Val and Lys939Gln polymorphisms in patients with breast cancer (n = 618)
| Features |
Total no. |
XPC Ala499Val | XPC Lys939Gln | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
CC No. (%) |
CT+TT No. (%) |
P [Link] | OR (95% CI)§ |
AA No. (%) |
AC+CC No. (%) |
P [Link] | OR (95% CI)§ | ||
| Age at diagnosis, years[Link] | 618 | 0.438 | 0.672 | ||||||
| ≤45 | 99 (16.0) | 226 (36.6) | 1.0 (ref.) | 115 (18.6) | 210 (34.0) | 1.0 (ref.) | |||
| >45 | 98 (15.9) | 195 (31.6) | 0.872 (0.621–1.223) | 98 (15.9) | 195 (31.6) | 1.090 (0.781–1.520) | |||
| Menopausal status | 618 | 0.603 | 0.309 | ||||||
| Premenopausal | 103 (16.7) | 231 (37.4) | 1.0 (ref.) | 109 (17.6) | 225 (36.4) | 1.00 (ref.) | |||
| Postmenopausal | 94 (15.2) | 190 (30.7) | 0.901 (0.642–1.265) | 104 (16.8) | 180 (29.1) | 0.838 (0.601–1.169) | |||
| First‐degree family history of breast cancer | 618 | 0.839 | 0.274 | ||||||
| No | 149 (24.1) | 323 (52.3) | 1.0 (ref.) | 157 (25.4) | 315 (51.0) | 1.00 (ref.) | |||
| Yes | 48 (7.8) | 98 (15.9) | 0.942 (0.634–1.400) | 56 (9.1) | 90 (14.6) | 0.801 (0.545–1.177) | |||
| Tumor size (cm) | 605 | 0.199 | 0.352 | ||||||
| ≤2.0 | 78 (12.9) | 181 (29.9) | NA | 83 (13.7) | 176 (29.1) | NA | |||
| 2.1–4.0 | 75 (12.4) | 170 (28.1) | NA | 93 (15.4) | 152 (25.1) | NA | |||
| ≥4.1 | 40 (6.6) | 61 (10.1) | NA | 33 (5.5) | 68 (11.2) | NA | |||
| Lymph node metastasis | 410 | 0.916 | 0.079 | ||||||
| Node‐negative | 69 (16.8) | 147 (35.8) | 1.0 (ref.) | 85 (20.7) | 131 (32.0) | 1.0 (ref.) | |||
| Node‐positive | 63 (15.4) | 131 (32.0) | 0.976 (0.645–1.478) | 60 (14.6) | 134 (32.7) | 1.449 (0.963–2.181) | |||
| Histology | 618 | 0.507 | 0.732 | ||||||
| DIC | 166 (26.9) | 364 (58.9) | NA | 185 (29.9) | 345 (55.8) | NA | |||
| LIC | 25 (4.0) | 41 (6.6) | NA | 22 (3.6) | 44 (7.1) | NA | |||
| Others | 6 (1.0) | 16 (2.6) | NA | 6 (1.0) | 16 (2.6) | NA | |||
| ER status | 610 | 0.011 | 0.438 | ||||||
| Negative | 98 (16.1) | 160 (26.2) | 1.0 (ref.) | 84 (13.8) | 174 (28.5) | 1.0 (ref.) | |||
| Positive | 99 (16.2) | 253 (41.5) | 1.565 (1.112–2.204) | 126 (20.7) | 226 (37.0) | 0.866 (0.617–1.216) | |||
| PR status | 609 | 0.078 | 0.795 | ||||||
| Negative | 90 (14.8) | 157 (25.8) | 1.0 (ref.) | 87 (14.3) | 160 (26.3) | 1.0 (ref.) | |||
| Positive | 107 (17.6) | 255 (41.9) | 1.366 (0.969–1.926) | 123 (20.2) | 239 (39.2) | 1.057 (0.752–1.484) | |||
| Her‐2 status | 600 | 0.019 | 0.384 | ||||||
| Negative | 41 (6.8) | 121 (20.2) | 1.0 (ref.) | 60 (10.0) | 102 (17.0) | 1.0 (ref.) | |||
| Positive | 155 (25.8) | 283 (47.2) | 0.619 (0.413–0.927) | 145 (24.2) | 293 (18.8) | 1.189 (0.816–1.731) | |||
| p53 status | 598 | 0.010 | 0.546 | ||||||
| Negative | 71 (11.9) | 197 (33.0) | 1.0 (ref.) | 97 (16.2) | 171 (28.6) | 1.0 (ref.) | |||
| Positive | 120 (20.1) | 209 (35.0) | 0.628 (0.441–0.893) | 111 (18.6) | 218 (36.5) | 1.114 (0.794–1.562) | |||
| BRCA1 status | 587 | 0.823 | <0.001 | ||||||
| Negative | 38 (6.5) | 77 (13.1) | 1.0 (ref.) | 19 (3.2) | 96 (16.4) | 1.0 (ref) | |||
| Positive | 149 (25.4) | 323 (55.0) | 1.070 (0.693–1.652) | 186 (31.7) | 286 (48.7) | 0.304 (0.180–0.515) | |||
| BRCA2 status | 574 | 0.235 | 0.789 | ||||||
| Negative | 79 (13.8) | 149 (26.0) | 1.0 (ref.) | 78 (13.6) | 150 (26.2) | 1.0 (ref.) | |||
| Positive | 103 (18.0) | 242 (42.2) | 1.246 (0.872–1.780) | 122 (21.3) | 223 (38.9) | 0.950 (0.669–1.351) | |||
†Median age was 45 years. ‡P‐ values were calculated from two‐sided χ2‐tests or Fisher's exact test. §Odds ratio (OR) and 95% confidence interval (CI) values were calculated by unconditional logistic regression adjusted for age and menopausal status. BRCA1, breast cancer type 1 susceptibility protein; BRCA2, breast cancer type 2 susceptibility protein; ER, estrogen receptor; DIC, ductal invasive carcinoma; LIC, lobular invasive carcinoma; Her‐2, human epidermal growth factor receptor‐2; NA, not applicable; p53, tumor protein 53; PR, progesterone receptor; ref., reference.